A new biotin derivative-DOTA conjugate as a candidate for pretargeted diagnosis and therapy of tumors

Giuseppina Sabatino, Marco Chinol, Giovanni Paganelli, Stefano Papi, Mario Chelli, Giuseppe Leone, Anna Maria Papini, Angelo De Luca, Mauro Ginanneschi

Research output: Contribution to journalArticlepeer-review

Abstract

The synthesis of a new biotin derivative, the (CO) reduced N-aminohexyl biotinamido derivative, designed to be serum biotinidase resistant, and its conjugation to the chelator DOTA through an amide bond at one of the four carboxymethyl chains are described. The 90Y-labeled conjugate was able to bind avidin at different Av/conjugate molar ratios with good results. The preclinical results indicate that this new biotin-DOTA conjugate is a good candidate for pretargeted diagnosis and therapy of tumors.

Original languageEnglish
Pages (from-to)3170-3173
Number of pages4
JournalJournal of Medicinal Chemistry
Volume46
Issue number14
DOIs
Publication statusPublished - Jul 3 2003

ASJC Scopus subject areas

  • Organic Chemistry

Fingerprint Dive into the research topics of 'A new biotin derivative-DOTA conjugate as a candidate for pretargeted diagnosis and therapy of tumors'. Together they form a unique fingerprint.

Cite this